open access

Online first
Original article
Published online: 2022-04-27
Get Citation

Quality of life in patients with a subcutaneous versus transvenous implantable cardioverter-defibrillator

Marta Jagosz1, Ewa Jędrzejczyk-Patej2, Wiktoria Kowalska1, Michał Mazurek2, Szymon Warwas1, Dominika Wiktor1, Adam Sokal2, Oskar Kowalski3, Radosław Lenarczyk4, Beata Średniawa4, Zbigniew Kalarus4
DOI: 10.33963/KP.a2022.0110
·
Pubmed: 35475461
Affiliations
  1. Student Scientific Society at the Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Katowice, Division of Medical Sciences in Zabrze, Zabrze, Poland
  2. Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
  3. Department of Dietetics, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland
  4. Division of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland, Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland

open access

Online first
Original article
Published online: 2022-04-27

Abstract

BACKGROUND: The implantable cardioverter-defibrillator (ICD) and subcutaneous cardioverter-defibrillator (S-ICD)  are well-accepted life-saving devices for potentially lethal ventricular arrhythmia but little is known about quality of life (QoL) in patients with S-ICD and ICD.

AIMS: The aim of our study was to compare QoL of patients with S-ICD and ICD.

METHODS: All consecutive patients who have had S-ICD implanted between October 2015 and September 2021 were included to the study. A cohort of TV-ICD patients was matched to S-ICD subjects by sex, age, indications for the device, and type of prevention. All patients were requested to fulfill two standardized questionnaires to assess QoL: 36-Item Short Form Health Survey (SF-36) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) 6 months after device implantation.

RESULTS: Patients with S-ICD (n = 49) and TV-ICD (n = 49) did not differ regarding baseline characteristics. There were no statistically significant differences between S-ICD and TV-ICD subgroup, both for mental and physical QoL assessed in SF-36 and MLHFQ (all P = NS). The median MLHFQ total score was 24 (941) for S-ICD and 28 (1443) for TV-ICD (P = 0.83). The median total score for the SF-36 questionnaire was 62.5 (2986) vs. 59 (3877) for S-ICD and TV-ICD, respectively (P = 0.78).

CONCLUSIONS: Quality of life after device implantation does not differ significantly between a group of patients with subcutaneous and conventional implantable cardioverter-defibrillator.

Abstract

BACKGROUND: The implantable cardioverter-defibrillator (ICD) and subcutaneous cardioverter-defibrillator (S-ICD)  are well-accepted life-saving devices for potentially lethal ventricular arrhythmia but little is known about quality of life (QoL) in patients with S-ICD and ICD.

AIMS: The aim of our study was to compare QoL of patients with S-ICD and ICD.

METHODS: All consecutive patients who have had S-ICD implanted between October 2015 and September 2021 were included to the study. A cohort of TV-ICD patients was matched to S-ICD subjects by sex, age, indications for the device, and type of prevention. All patients were requested to fulfill two standardized questionnaires to assess QoL: 36-Item Short Form Health Survey (SF-36) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) 6 months after device implantation.

RESULTS: Patients with S-ICD (n = 49) and TV-ICD (n = 49) did not differ regarding baseline characteristics. There were no statistically significant differences between S-ICD and TV-ICD subgroup, both for mental and physical QoL assessed in SF-36 and MLHFQ (all P = NS). The median MLHFQ total score was 24 (941) for S-ICD and 28 (1443) for TV-ICD (P = 0.83). The median total score for the SF-36 questionnaire was 62.5 (2986) vs. 59 (3877) for S-ICD and TV-ICD, respectively (P = 0.78).

CONCLUSIONS: Quality of life after device implantation does not differ significantly between a group of patients with subcutaneous and conventional implantable cardioverter-defibrillator.

Get Citation

Keywords

quality of life, implantable cardioverter-defibrillator, subcutaneous cardioverter-defibrillator, prognosis

About this article
Title

Quality of life in patients with a subcutaneous versus transvenous implantable cardioverter-defibrillator

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Original article

Published online

2022-04-27

Page views

77

Article views/downloads

73

DOI

10.33963/KP.a2022.0110

Pubmed

35475461

Keywords

quality of life
implantable cardioverter-defibrillator
subcutaneous cardioverter-defibrillator
prognosis

Authors

Marta Jagosz
Ewa Jędrzejczyk-Patej
Wiktoria Kowalska
Michał Mazurek
Szymon Warwas
Dominika Wiktor
Adam Sokal
Oskar Kowalski
Radosław Lenarczyk
Beata Średniawa
Zbigniew Kalarus

References (24)
  1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). EP Europace. 2015; 17(11): 1601–1687.
  2. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007; 115(19): 2474–2480.
  3. Kempa M, Przybylski A, Budrejko S, et al. Evolution of implantation technique and indications for a subcutaneous cardioverter-defibrillator: over 7 years of experience in Poland. Kardiol Pol. 2021; 79(9): 1016–1018.
  4. Kempa M, Przybylski A, Budrejko S, et al. Multicenter registry of subcutaneous cardioverter-defibrillator implantations: a preliminary report. Kardiol Pol. 2021; 79(6): 697–699.
  5. Sears SF. Jr., Conti JB. Quality of life and psychological functioning of ICD patients. Heart. 2002; 87: 488–493.
  6. Gribbin GM, Kenny RA, McCue P, et al. Individualised quality of life after pacing. Does mode matter? Europace. 2004; 6(6): 552–560.
  7. Connolly S, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Psychologic Pac- ing Investigators. N Engl J Med. 2000; 342: 1385–1391.
  8. Lamas GA, Orav E, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Se- lection in the Elderly Investigators. N Engl J Med. 1998; 338: 1097–1104.
  9. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013; 34(3): 211–219.
  10. Goldenberg I, Gillespie J, Moss AJ, et al. Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010; 122(13): 1265–1271.
  11. Köbe J, Hucklenbroich K, Geisendörfer N, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol . 2017; 106(5): 317–321.
  12. Pedersen SS, Mastenbroek MH, Carter N, et al. A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life Substudy). Am J Cardiol. 2016; 118(4): 520–526.
  13. Pedersen SS, Carter N, Barr C, et al. Quality of life, depression, and anxiety in patients with a subcutaneous versus transvenous defibrillator system. Pacing Clin Electrophysiol. 2019; 42(12): 1541–1551.
  14. Mastenbroek MH, Versteeg H, Jordaens L, et al. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort. Psychosom Med. 2014; 76(1): 58–65.
  15. Nefs G, Speight J, Pouwer F, et al. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005; 67(1): 89–97.
  16. Godemann F, Ahrens B, Behrens S, et al. Classic Conditioning and Dysfunctional Cognitions in Patients With Panic Disorder and Agoraphobia Treated With an Implantable Cardioverter/Defibrillator. Psychosom Med. 2001; 63(2): 231–238.
  17. Pedersen SS, Van Den Broek KC, Van Den Berg M, et al. Shock as a determinant of poor patient-centered outcomes in implantable cardioverter defibrillator patients: is there more to it than meets the eye? Pacing Clin Electrophysiol. 2010; 33(12): 1430–1436.
  18. Lewandowski M, Syska P, Kowalik I. Children and young adults treated with transvenous and subcutaneous implantable cardioverter-defibrillators: a 22-year single-center experience and new perspectives. Kardiol Pol. 2020; 78(9): 869–874.
  19. Habibović M, Versteeg H, Pelle AJM, et al. Poor health status and distress in cardiac patients: the role of device therapy vs. underlying heart disease. Europace. 2013; 15(3): 355–361.
  20. Pedersen SS, Versteeg H, Nielsen JC, et al. Patient-reported outcomes in Danish implantable cardioverter defibrillator patients with a Sprint Fidelis lead advisory notification. Europace. 2011; 13(9): 1292–1298.
  21. Hammash M, McEvedy SM, Wright J, et al. Perceived control and quality of life among recipients of implantable cardioverter defibrillator. Aust Crit Care. 2019; 32(5): 383–390.
  22. Israelsson J, Thylén I, Strömberg A, et al. Factors associated with health-related quality of life among cardiac arrest survivors treated with an implantable cardioverter-defibrillator. Resuscitation. 2018; 132: 78–84.
  23. Dunbar SB, Kimble LP, Jenkins LS, et al. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress Anxiety. 1999; 9(4): 163–168, doi: 10.1002/(sici)1520-6394(1999)9:4<163::aid-da3>3.0.co;2-b.
  24. Carroll DL, Hamilton GA. Quality of life in implanted cardioverter defibrillator recipients: the impact of a device shock. Heart Lung. 2005; 34(3): 169–178.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl